Last updated: April 24, 2026
What product format is in scope?
“Clindamycin phosphate in dextrose 5%” is an IV admixture that uses:
- API: clindamycin phosphate (parenteral)
- Diluent/infusion solution: Dextrose 5% (D5W)
This is typically supplied as:
- Commercially manufactured injectable clindamycin phosphate (concentrate/strengths) plus D5W for pharmacy reconstitution, or
- Pre-manufactured diluted infusion product where available (less common; varies by market and label).
Who are the typical supplier categories?
Suppliers fall into four practical buckets:
- Finished-dose manufacturer (clindamycin phosphate injectable)
- API manufacturer (clindamycin phosphate active pharmaceutical ingredient)
- Diluent supplier (Dextrose 5% injection)
- Distributor (delivers finished product and/or infusion components to hospitals and pharmacies)
Finished-dose suppliers (clindamycin phosphate injectable used for dilution into D5W)
The following multinational manufacturers have established lines for clindamycin phosphate injection that are commonly used as the starting product for dilution into D5W in hospital pharmacy workflows:
| Supplier (Company) |
Product role in “in D5W” preparations |
Notes for procurement |
| Pfizer |
Finished-dose clindamycin phosphate injection (source API for D5W dilution) |
Common global injectable supplier footprint |
| Hospira (Pfizer) |
Finished-dose injectable clindamycin phosphate (legacy and ongoing channels in many markets) |
Often present in hospital distribution networks |
| Sandoz (Novartis) |
Finished-dose injectable clindamycin phosphate |
Frequent hospital procurement inclusion via generic portfolios |
| Dr. Reddy’s |
Finished-dose clindamycin phosphate injection |
Generic injectable manufacturer |
| Teva |
Finished-dose injectable clindamycin phosphate |
Generic injectable lines and distribution |
| Cipla |
Finished-dose injectable clindamycin phosphate |
Generic injectable lines and distribution |
API suppliers (clindamycin phosphate)
Clindamycin phosphate API is supplied through multiple global active ingredient plants. In procurement terms, API supply is usually contracted via:
- API distributors and brokers,
- CDMO/API partnerships,
- Finished-dose manufacturers’ internal qualified supplier lists.
For the specific drug name “clindamycin phosphate” (API), common qualified supply sources in the industry include established API producers across India and China. However, API sourcing is not consistently published at the same granularity as finished-dose labels in routine procurement catalogs.
D5W (Dextrose 5% injection) diluent suppliers
D5W is widely manufactured as a commodity parenteral diluent and is sourced from large sterile injectable suppliers. Procurement usually points to the diluent label rather than the antibiotic-specific label.
Common finished diluent suppliers in major markets include:
| Supplier (Company) |
Product role |
Notes |
| B. Braun |
Dextrose 5% injection (diluent) |
Large sterile portfolio |
| Fresenius Kabi |
Dextrose 5% injection (diluent) |
Global sterile injectables presence |
| Hospira |
Dextrose 5% injection (diluent) |
Strong hospital channel presence |
| McGuff |
Dextrose 5% injection (diluent) |
Relevant in US distributor networks for some SKUs |
| Braun Medical / Braun brands |
Dextrose 5% injection (diluent) |
Region-dependent listing |
Distributor channels (how hospitals typically source the combination)
Most hospitals do not buy “clindamycin phosphate in D5%” as one universal SKU. They purchase:
- clindamycin phosphate injectable concentrate plus
- D5W bags (or vials)
then prepare the infusion via internal pharmacy compounding.
Typical distributor routes include:
- Cardinal Health
- McKesson
- AmerisourceBergen (Cencora)
Procurement reality: how to specify purchasing SKUs
To operationalize procurement, buyers generally order two items:
- Clindamycin phosphate injectable (strength and presentation)
- example label descriptors: “clindamycin phosphate injection” (concentration varies by market)
- Dextrose 5% injection (bag/vial size)
- example label descriptors: “Dextrose 5% injection, USP” (size varies)
Key takeaways
- “Clindamycin phosphate in dextrose 5%” is usually produced by hospital pharmacy dilution of clindamycin phosphate injection with D5W rather than one universal finished product SKU.
- Primary supplier targets are: finished-dose clindamycin phosphate injectables, D5W diluent manufacturers, and major distributors for channel access.
- For contracting and sourcing, specify orders as two SKUs: clindamycin phosphate injection plus D5W injection.
FAQs
-
Is “clindamycin phosphate in dextrose 5%” normally a single commercial product SKU?
Usually no; it is commonly prepared by dilution using clindamycin phosphate injection and D5W.
-
Who supplies the diluent for these IV admixtures?
D5W is supplied by large sterile injectable manufacturers such as B. Braun and Fresenius Kabi in many markets.
-
What should purchasing teams request if they need the infusion-ready admixture?
The standard approach is to order clindamycin phosphate injectable and D5W separately, then compound in-house or via a contract compounding pharmacy.
-
Are clindamycin phosphate suppliers the same as D5W suppliers?
No. Clindamycin phosphate is an antibiotic injectable product; D5W is a diluent commodity product supplied by a different sterile manufacturing base.
-
Which distributors most commonly deliver both components to hospitals?
Cardinal Health, McKesson, and Cencora are common US distribution channels.
References
[1] FDA. “Drug Approval Package: Clindamycin Phosphate.” U.S. Food and Drug Administration.
[2] DailyMed. “Clindamycin Phosphate Injection (Product Label Information).” U.S. National Library of Medicine.
[3] DailyMed. “Dextrose 5% Injection, USP (Product Label Information).” U.S. National Library of Medicine.
[4] Cardinal Health. Hospital pharmaceutical distribution and supply services information.
[5] McKesson. Hospital distribution and sterile supplies information.
[6] Cencora (AmerisourceBergen). Hospital pharmaceutical distribution and procurement channel information.
